Satellos

Satellos Bioscience

This company develops oral small molecule drugs to restore muscle regeneration for patients with Duchenne muscular dystrophy and other degenerative muscle diseases.

Edgewise Therapeutics

This biopharmaceutical company develops small molecule therapies for patients with serious cardiovascular diseases and musculoskeletal conditions like Duchenne and Becker muscular dystrophy.

MyoPax

This company develops muscle regeneration cell and gene therapies for patients with congenital malformations, trauma, hereditary dystrophies and muscle wasting disorders.

Augustine Therapeutics

This company develops small molecule inhibitors to treat patients with neuromuscular, neurodegenerative and cardio-metabolic diseases.

NMD Pharma

This company develops small molecule therapies for patients suffering from severe neuromuscular disorders to restore skeletal muscle function.

Exonics

This company develops gene editing therapies for patients with Duchenne muscular dystrophy and other severe genetic neuromuscular diseases.

MyoGene Bio

This company develops gene-editing therapies to treat patients with Duchenne muscular dystrophy by restoring production of the dystrophin protein.

Capricor

This biotechnology company develops cell and exosome-based therapies to treat Duchenne muscular dystrophy and other serious diseases for patients.